Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.80 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.80 |
| ▸ | DRD2 | P14416 | 1/20 | 0.80 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.80 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.80 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.80 |
| ▸ | MAOA | P21397 | 1/20 | 0.80 |
| ▸ | HTR2A | P28223 | 1/20 | 0.80 |
| ▸ | HTR2C | P28335 | 1/20 | 0.80 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.80 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.80 |
| ▸ | HRH1 | P35367 | 1/20 | 0.80 |
| ▸ | DRD3 | P35462 | 1/20 | 0.80 |
| ▸ | HTR2B | P41595 | 1/20 | 0.80 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.80 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.80 |
| ▸ | BCHE | P06276 | 3/20 | 0.57 |
| ▸ | ACHE | P22303 | 3/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31238163 | 0.99 | CHRM2 (0.79) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL7877715 | 0.97 | CHRM2 (0.80) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL11102962 | 0.93 | CHRM2 (0.74) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL16054480 | 0.93 | CHRM2 (0.74) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL11101602 | 0.92 | CHRM2 (0.76) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL11552114 | 0.91 | CHRM2 (0.74) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL2912554 | 0.90 | CHRM2 (0.73) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| SCHEMBL31447589 | 0.90 | CHRM2 (0.73) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| Nitracrine SCHEMBL29399539 | 0.90 | HRH1 (1.00) | CHRM2CHRM1DRD2ADRA2BADRA2C | |
| Nitracrine SCHEMBL8807 | 0.90 | HRH1 (1.00) | CHRM2CHRM1DRD2ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010031763-A1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | SMITHKLINE BEECHAM CORPORATION | 2001-10-18 | — | — | US | claimed |
| EP-0979078-A4 | SUBSTITUTED BIS-ACRIDINES AND RELATED COMPOUNDS AS CCR5 RECEPTOR LIGANDS, ANTI-INFLAMMATORY AGENTS AND ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORP (US) | 2000-06-21 | — | — | EP | claimed |
| EP-0979078-A1 | SUBSTITUTED BIS-ACRIDINES AND RELATED COMPOUNDS AS CCR5 RECEPTOR LIGANDS, ANTI-INFLAMMATORY AGENTS AND ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-16 | — | — | EP | claimed |
| WO-1998030218-A1 | SUBSTITUTED BIS-ACRIDINES AND RELATED COMPOUNDS AS CCR5 RECEPTOR LIGANDS, ANTI-INFLAMMATORY AGENTS AND ANTI-VIRAL AGENTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-07-16 | — | — | WO | claimed |
| US-20010031763-A1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | SMITHKLINE BEECHAM CORPORATION | 2001-10-18 | — | — | US | disclosed |
| US-6242459-B1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | SMITHKLINE BEECHAM CORPORATION | 2001-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010031763-A1 | Substituted bis-acridines and related compounds as CCR5 receptor ligands, anti-inflammatory agents and anti-viral agents | CCR5, CCR2, CCR1 | CHRM2 448/4885CHRM1 405/4885DRD2 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.